Dainippon Sumitomo Seeks Added Uses For AmBisome Anti-Fungal
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma has filed for additional indications for its anti-fungal AmBisome (amphotericin). The company is believed to be asking for several additional fungi to be added to the three it now has approval for, but it would not say how many or which. The drug already has Japanese approval for treating aspergillus, candida and cryptococcus. Dainippon applied under a system that could allow approval of the additional uses without being subjected to new clinical trials. (Click here for more - a subscription may be required